10 Promising Players of Liquid Biopsy Market With Market Size | Suppliers 2025

10 Promising Players of Liquid Biopsy Market With Market Size

The liquid biopsy market is rapidly evolving, with several key players leading innovation and development. Companies like Bio-Rad Laboratories, Guardant Health, and Roche Molecular Diagnostics are at the forefront, pioneering new technologies and comprehensive solutions that enhance the detection, monitoring, and treatment of various cancers. These companies, among others, are instrumental in shaping the liquid biopsy landscape, driving research and development to make this non-invasive testing method a standard in oncology diagnostics and patient management. Liquid biopsy has the potential to revolutionize cancer care by providing early detection, monitoring, and personalized treatment options.

By analyzing tumor-derived biomarkers in biofluids like blood, urine, or cerebrospinal fluid, liquid biopsy offers a less invasive alternative to tissue biopsies while still providing valuable genetic information. This not only reduces patient discomfort but also allows for more frequent testing and monitoring of disease progression. Additionally, liquid biopsy can capture the heterogeneity of tumors, giving a more comprehensive understanding of the disease and potentially identifying resistance to therapy. As per 6Wresearch, as of 2025, the market size is estimated to be approximately $3.5 billion. Analysts forecast that the market will continue to grow at a CAGR of around 25% over the next five years. By 2031, the market size is expected to reach nearly $7.2 billion.

List of Leading Companies in the Liquid Biopsy Market

1. Qiagen N.V.

Qiagen is a leading global provider of sample and assay technologies, offering a comprehensive portfolio for molecular diagnostics, applied testing, and academic and pharmaceutical research. Their liquid biopsy solutions aim to improve non-invasive cancer detection and monitoring.

2. Roche Diagnostics

Roche Diagnostics is part of the Roche Group and is known for its innovations in the healthcare sector. The company focuses on advancing liquid biopsy technologies to improve patient outcomes through enhanced precision in cancer diagnostics.

3. Biocept, Inc.

Biocept is dedicated to enhancing cancer treatment decisions with its advanced liquid biopsy tests. The company offers a range of clinical assays for solid tumor indications, leveraging the power of circulating tumor cells and cell-free circulating tumor DNA.

4. Guardant Health, Inc.

Guardant Health is at the forefront of developing cutting-edge technology for comprehensive genomic profiling. Their Guardant360 test is a widely used liquid biopsy that assists oncologists in personalizing cancer treatment plans.

5. Thermo Fisher Scientific

Thermo Fisher Scientific is a global leader in serving science, providing innovative tools for researchers. Their liquid biopsy technologies focus on advancing precision medicine and enabling improved cancer management solutions.

6. Illumina, Inc.

Illumina is known for its DNA sequencing and array-based technologies. The company is driving innovations in liquid biopsy with next-generation sequencing (NGS) solutions that facilitate early cancer detection and monitoring.

7. Foundation Medicine, Inc.

Part of the Roche Group, Foundation Medicine focuses on expanding the benefits of precision medicine through its liquid biopsy assays. Their comprehensive genomic tests help clinicians make informed decisions for cancer treatment.

8. Menarini Silicon Biosystems

Menarini Silicon Biosystems offers a unique platform for liquid biopsy, which provides reliable and reproducible analysis of rare cells. They focus on enabling high-throughput and detailed cellular analysis for cancer research and diagnostics.

9. Freenome

Freenome is applying its multiomics platform to revolutionize the early detection of cancer using liquid biopsy methodologies. The company combines data from proteins, DNA, and other molecules to improve predictive health capabilities.

10. Sysmex Corporation

Sysmex provides innovative solutions for clinical laboratories. Their liquid biopsy tests explore the potential of using blood samples for effective cancer diagnosis, focusing on the analysis of circulating tumor cells and genomic biomarkers.

Frequently Asked Questions About the Market Study (FAQs):